Immune checkpoint inhibitors in melanoma in the metastatic, neoadjuvant, and adjuvant setting
Purpose of review
Immune checkpoint inhibitors (ICI) are now standards of care in metastatic melanoma. We highlight here the dramatic improvement that these drugs brought in the history of melanoma care.
Recent findings
The monoclonal antibody directed against cytotoxic T-lymphocyte-associated protein 4, ipilimumab, was approved in 2011. Antiprogramed death cell protein 1 antibodies, nivolumab and pembrolizumab, were developed afterward and approved in 2014, demonstrating an improved efficacy/safety ratio as compared with ipilimumab. The association of ipilimumab and nivolumab now appears as the most efficient immunot...
Source: Current Opinion in Oncology - February 6, 2020 Category: Cancer & Oncology Tags: MELANOMA AND OTHER SKIN NEOPLASMS: Edited by Céleste Lebbe Source Type: research
Use of noninvasive imaging in the management of skin cancer
Purpose of review
To evaluate noninvasive imaging techniques in the management of skin cancers.
Recent findings
In the last decades, a wide range of noninvasive imaging methods has been developed in the field of dermatooncology with the aim to detect and assess the several structural and molecular changes that characterize skin cancer development and progression.
Summary
In this review, we discuss the current and emerging applications of noninvasive imaging approaches in skin cancer management, such as digital photography, dermoscopy, ultrasound sonography, reflectance confocal microscopy, optical coherence tomogra...
Source: Current Opinion in Oncology - February 6, 2020 Category: Cancer & Oncology Tags: MELANOMA AND OTHER SKIN NEOPLASMS: Edited by Céleste Lebbe Source Type: research
Mechanisms of resistance and predictive biomarkers of response to targeted therapies and immunotherapies in metastatic melanoma
Purpose of review
Thanks to mitogen-activated protein kinase inhibitors (MAPKi) and immune checkpoint inhibitors (ICI), major progress has been made in the field of melanoma treatment. However, long-term success is still scarce because of the development of resistance. Understanding these mechanisms of resistance and identifying predictive genomic biomarkers are now key points in the therapeutic management of melanoma patients.
Recent findings
Multiple and complex mechanisms of resistance to MAPKi or ICI have been uncovered in the past few years. The lack of response can be driven by mutations and nonmutational events...
Source: Current Opinion in Oncology - February 6, 2020 Category: Cancer & Oncology Tags: MELANOMA AND OTHER SKIN NEOPLASMS: Edited by Céleste Lebbe Source Type: research
Targeting BRAF and MEK inhibitors in melanoma in the metastatic, neoadjuvant and adjuvant setting
Purpose of review
Better understanding of the biology of BRAF-mutated melanoma has led to the development of highly effective therapy, BRAF and MEK inhibitors, targeting abnormally activated protein kinases for patient with BRAF-mutated melanoma. The purpose of this article was to review the recent published data on BRAF and MEK inhibitors in melanoma in the metastatic, adjuvant and neoadjuvant setting to facilitate the management of melanoma patients in clinical practice.
Recent findings
The spectacular outcomes of targeted therapy in advanced melanoma patients have led to their development in the adjuvant setting wi...
Source: Current Opinion in Oncology - February 6, 2020 Category: Cancer & Oncology Tags: MELANOMA AND OTHER SKIN NEOPLASMS: Edited by Céleste Lebbe Source Type: research
Targeted therapies in melanoma beyond BRAF: targeting NRAS-mutated and KIT-mutated melanoma
Purpose of review
Melanoma treatment have been revolutionized since 2010 by the development of immune checkpoint inhibitors, and, for BRAF-mutated melanoma, targeted therapies based on BRAF and MEK inhibitors, which is a model of effective targeted therapy in cancer. However, patients with BRAF wild type cannot benefit for such treatments. In this review, we will focus on the current clinical development of targeted therapies beyond BRAF, in NRAS-mutated and KIT-altered melanoma.
Recent findings
In NRAS-mutated melanoma, targeted therapies based on MEK inhibition are being developed as monotherapy or in combination wi...
Source: Current Opinion in Oncology - February 6, 2020 Category: Cancer & Oncology Tags: MELANOMA AND OTHER SKIN NEOPLASMS: Edited by Céleste Lebbe Source Type: research
